New Alzheimer's drug slows cognitive decline by 27%, clinical trial finds
Published
Lecanemab, a drug made by Eisai and Biogen, was observed in a large-scale trial to have slowed the disease's progression by 27% over 18 months.
Full ArticlePublished
Lecanemab, a drug made by Eisai and Biogen, was observed in a large-scale trial to have slowed the disease's progression by 27% over 18 months.
Full ArticleA new drug found to reduce cognitive decline in early-stage Alzheimer's has been hailed as an "historic moment" in the treatment of..